Ynno Med

By 2050, antimicrobial infections are projected to cause 10 million deaths worldwide, outracing cancers. Therefore, new antimicrobial agents are urgently needed before the existing ones become ineffective. Ynno Med developed an AI-assisted platform for discovering new drugs, specializing in the infectious disease area. They address the unmet clinical needs of new antimicrobial agents tackling antimicrobial resistance. As a university spin-off company, YnnoMed is commercializing the scientific and technological findings obtained from research activities to utilize the otherwise unexploited knowledge. As a drug R&D company, their goal is to design, develop, and distribute first-in-class antimicrobial medicines that can treat current antibiotic-resistant bacterial infections and suppress the generation of new antimicrobial resistance. Additionally, they can also provide drug design and discovery services, using their technology to facilitate industrial development.